Nektar Therapeutics
Nektar Therapeutics (NKTR) — Form SCHEDULE 13G/A: Ownership over 5% (passive) (amendment)
About this filing
Nektar Therapeutics (NKTR) filed Form SCHEDULE 13G/A (ownership over 5% (passive) (amendment)) with the SEC on Sep 28, 2026. A Schedule 13G reports a passive investor owning more than 5% of the company.
Key facts
- Document
- —
More NKTR filings
- S-8
Filed Oct 19, 2026
- 8-K
Filed Oct 1, 2026
- 4
Filed Sep 25, 2026
- 4
Filed Sep 25, 2026
- 4
Filed Sep 25, 2026
- 4
Filed Sep 25, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.